Bone is constantly remodeled to maintain its volume, structural integrity and 
strength Currently available bone anabolic agent is teriparatide. Teriparatide 
increases bone mass and strength via both remodeling-dependent and -independent 
mechanisms, although remodeling-dependent mechanism overweighs the other. 
Canonical Wnt signal plays an important role in enhancing osteoblast 
differentiation and bone formation, and its osteocyte-derived inhibitor, 
sclerostin, regulates bone formation via the regulation of Wnt signaling. 
Anti-sclerostin antibody stimulates Wnt signaling and enhances bone formation. 
Phase II clinical trials with anti-sclerostin antibodies, romosozumab and 
blosozumab, demonstrated a marked increase in bone mineral density after one 
year of treatment. The new modality of anabolic agents via 
remodeling-independent stimulation of bone formation may open up a new avenue 
for the treatment of osteoporosis.